Scientists explored the potential of PrsA1 and PrsA2 as vaccine candidates for preventing Group A Streptococcus (GAS) infection. We found that PrsA1 and PrsA2 are highly conserved among GAS isolates, demonstrating minimal amino acid variation.
[NPJ Vaccines]